Onconetix, (NASDAQ: ONCO) — Perfil da empresa, notícias e dados financeiros
Onconetix is an oncology company developing targeted cancer therapies through research, clinical trials and academic collaborations.

Onconetix,
Onconetix (NASDAQ:ONCO) is dedicated to pioneering advancements in cancer treatment through its targeted research and development projects. The company focuses on creating innovative therapies aimed at improving patient outcomes and contributing to the global fight against cancer. Onconetix's objectives center around harnessing cutting-edge science and technology to develop treatments that can effectively target and combat various types of cancer at different stages. Their operations span from early-stage research to clinical trials, with a committed team working tirelessly to translate scientific discoveries into real-world applications. Onconetix aims to establish a robust pipeline of oncology products by leveraging partnerships, academic collaborations, and strategic investments to accelerate the development and availability of groundbreaking cancer therapies.
Resumo
Operações
Produtos e/ou serviços de Onconetix,
- Development of targeted therapies for various cancers focusing on precision medicine.
- Research on biomarkers for early cancer detection and treatment efficiency monitoring.
- Creation of a proprietary drug delivery platform to enhance the efficacy of chemotherapy.
- Partnerships with pharmaceutical companies for the co-development of cancer therapeutics.
- Provision of genomics profiling services to support personalized medicine.
- Implementation of artificial intelligence in drug discovery and development processes.
equipe executiva do Onconetix,
- Karina M. FedaszInterim Chief Financial Officer
- David Allan WhiteChief Executive Officer
- Andrew D. SkiboGlobal Head of Biologics Operations
- Theodore Scott YohoHead of Business Development
- Ali I. FattomHead of Science & Discovery
- Jay NewmarkChief Medical Officer
Principais indicadores financeiros
Resultados divulgados pela Onconetix,, em USD.
- Cap. de mercado
- 3,6 mi
- Receita (TTM)
- 645,8 mil
- P/L
- 0.0
- LPA (diluído, TTM)
- 310.4
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 815,4 mil | -6,3 mi | -14 mi | |
| 2,5 mi | -56,5 mi | -58,7 mi | |
| 58,5 mil | -36 mi | -37,4 mi | |
| 0 | -13,5 mi | -13,4 mi |